Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue...
Otonomy (OTIC) Q2 2022 Earnings Call Transcript
OTIC earnings call for the period ending June 30, 2022.
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and...
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...